"While with Roche I enjoyed working with Beat Widler in his function as head of Clinical Quality Assurance. He was one of my direct reports whose pragmatic approach towards and solid knowledge of GCP and quality management I have particularly valued. It is with great enthusiasm that Beat Widler and Peter Schiemann have developed a unique quality risk management approach for the Roche Development organization. This moved the QA function to new frontiers by clearly demonstrating the benefits in terms of quality and efficiency." - Dr. Holdener, Chairman of the Board of Novimmune and Emeritus Head of Roche Global Pharma Development
"Peter and Beat could always be relied on to engage practically in ensuring that clinical activities were always run in full compliance and adherence with regulatory and ethical standards.This went across all phases of trials and were designed to meet the goals of the teams." - William Burns, Member of the Roche Board and former CEO of Roche’s Pharma Division
"I have known Beat for many years, and in that time have seen him pioneer new ways of doing things that have benefitted his company. Beat was one of the first in our industry group to talk about risk management. He is still ahead of his time, and looking for creative ways around the problems we all wrestle with. Beat delivers on a project when he has committed, and he can always be counted on for a well-informed, thoroughly researched viewpoint." - Paul Strickland, Global R&D Compliance
